New Vaccine Blocks Covid-19, Variants, Other Coronaviruses: Study

New vaccine developed has proven effective against the original SARS-CoV-1, SARS-CoV-2 as well as its UK, South Africa and Brazil variants and Brazil variants and related bat Coronaviruses.

New vaccine developed by the US researchers was found to be effective against the original SARS-CoV-1, SARS-CoV-2 and even against its UK, South Africa and Brazil variants and related bat Coronaviruses.

The new vaccine, called //pan-coronavirus vaccine, was found effective in protecting monkeys and mice.

US Rolls Out Walk-in Covid Vaccines in Mobile Clinics
United States has rolled out walk-in COVID-19 vaccines in pharmacies and mobile clinics, reported the media. Retail chains have announced vaccines to walk-in clients at some locations or in mobile clinics.

‘Pan-coronavirus vaccine can block the virus 100%. Researchers designed a nanoparticle displaying the vulnerable spot. The nanoparticle is combined with a small molecule adjuvant, which boosts the body's immune response to fight the disease.’

Pan-coronavirus vaccine triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the Coronavirus part that allows it to bind to the body's cell receptors and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans, said researchers from the Duke University in North Carolina, US.

The findings, published in the journal Nature, showed that the nanoparticle vaccine, in monkeys, blocked Covid-19 infection by 100 percent. The new vaccine also elicited significantly higher neutralizing levels in the animals than current vaccine platforms or natural infection in humans.

"We began this work last spring with the understanding that, like all viruses, mutations would occur in the SARS-CoV-2 virus, which causes Covid-19," said senior author Barton F Haynes, director of the Duke Human Vaccine Institute (DHVI).

WHO Experts to Provide Guidelines on Moderna's COVID Vaccine
World Health Organization (WHO) panel of vaccine experts is set to issue recommendations on Moderna's COVID-19 vaccine on Tuesday.

"The mRNA vaccines were already under development, so we were looking for ways to sustain their efficacy once those variants appeared.

"This approach not only provided protection against SARS-CoV-2, but the antibodies induced by the vaccine also neutralized variants of concern that originated in the UK, South Africa and Brazil. And the induced antibodies reacted with quite a large panel of coronaviruses," Haynes said.

Sinovac Covid Vaccine to Be Reviewed by EMA
Sinovac, the Chinese company will be evaluated by the European Medicine Agency (EMA) under usual European Union (EU) standards for effectiveness, safety and quality.

The team built on earlier studies involving SARS, the respiratory illness caused by a coronavirus called SARS-CoV-1. They found a person who had been infected with SARS developed antibodies capable of neutralizing multiple coronaviruses, suggesting that a pan-coronavirus might be possible.

They identified one particular receptor-binding domain site that is present on SARS-CoV-2, its circulating variants and SARS-related bat viruses that makes them highly vulnerable to cross-neutralizing antibodies.

Pfizer-BioNTech COVID Vaccine Very Effective Against Variants
The Pfizer-BioNTech Coronavirus vaccine is found to be highly effective against severe pneumonia and death.

The team then designed a nanoparticle displaying this vulnerable spot. The nanoparticle is combined with a small molecule adjuvant, which boosts the body's immune response to fight the disease.

Source-IANS